SVRA - NASDAQ

Savara Inc.

SVRA·NASDAQ

$5.32

+1.4%

HealthcareBiotechnology

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.09B

EPS-0.5300

P/E Ratio-10.05

Earnings Date08/06/2026

svra

EPS

Last Annual Value

-0.53

3-Year CAGR

-28%

5-Year CAGR

10-Year CAGR

29%

Adjust for Inflation

Savara Inc. Competitors Analysis of EPS

SVRA · NASDAQ

Company	EPS	CAGR 3Y	CAGR 5Y	CAGR 10Y
Savara Inc. NASDAQ:SVRA	-0.53	N/A	N/A	N/A
Kura Oncology, Inc. NASDAQ:KURA	-3.18	N/A	N/A	N/A
Geron Corporation NASDAQ:GERN	-0.13	N/A	N/A	N/A
Rezolute, Inc. NASDAQ:RZLT	-0.98	N/A	N/A	N/A
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX	-2.52	N/A	N/A	N/A
Tango Therapeutics, Inc. NASDAQ:TNGX	-0.87	N/A	N/A	N/A
Tyra Biosciences, Inc. NASDAQ:TYRA	-2.01	N/A	N/A	N/A
EyePoint Pharmaceuticals, Inc. NASDAQ:EYPT	-3.17	N/A	N/A	N/A
ProKidney Corp. NASDAQ:PROK	-0.52	N/A	N/A	N/A

Savara Inc. Fair Value Envelope

SVRA · NASDAQ

Our analysis suggests that SVRA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.3249, this represents a potential HIDDEN relative to our calculated worth for Savara Inc..

HIDDEN

Intrinsic Value

Current Price: $5.3249

Related Guides

Blog Categories

Continue your SVRA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.